Friday, July 15, 2011
Advanced Cell Technology announced the dosing of the first patients in each of its two phase I/II clinical trials for Stargardt’s macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were treated by Steven Schwartz, M.D., at the David Geffen School of Medicine at UCLA. Robert Lanza, M.D., chief scientific officer of ACT, attended the procedures. Both patients successfully underwent the outpatient transplantation surgeries and are recovering uneventfully.